絞り込み

16645

広告

新型ウイルス肺炎 北朝鮮国営航空 外国人観光客は乗せない対応

中国で新型のコロナウイルスによるものとみられる肺炎への感染が広がっている問題を受けた北朝鮮の動きです。北朝鮮国営のコリョ(高麗)航空はNHKの取材に対し、北京か...

  1. 新型ウイルス肺炎 マカオでも感染者を初確...
  2. 調達情報 中小企業のための女性活躍推進事...
  3. 調達情報 民間人材サービスの活用検討事業...
  4. 書店水槽に「ぴろぴろの何か」 絶滅危惧ド...

ニュース一覧

Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.

著者 Baba K , Tanaka H , Sakamoto H , Shiratori T , Tsuchiya J , Ishioka Y , Itoga M , Taima K , Tasaka S
Thorac Cancer.2019 Jan 02 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (138view , 0users)

Full Text Sources

Miscellaneous

Pembrolizumab has become the standard first-line treatment for non-small cell lung cancer (NSCLC) patients with high PD-L1expression. MET exon 14 skipping is a rare mutation typically found in older, female, and non-smoking patients with NSCLC. Herein, we report the case of a 71-year-old non-smoking woman who was diagnosed with NSCLC in the left lung. EGFR mutation and ALK fusion were not detected. Because the biopsy specimen showed high PD-L1 expression with a tumor proportion score of 95%, pembrolizumab was introduced as first-line therapy, but resulted in no clinical benefit. The patient was subsequently administered chemotherapy with carboplatin and pemetrexed, leading to remarkable tumor shrinkage. A next-generation sequencing panel analysis revealed a MET exon 14 skipping mutation. Thus, pembrolizumab might not be effective for NSCLC patients with MET exon 14 skipping mutations, even if PD-L1 expression is high.
PMID: 30600919 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード